Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanhong Huoxue Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Jiangxi Huiren Pharmaceutical Co., Ltd. for the treatment of chronic stable angina pectoris. The drug is designed to promote blood circulation, resolve blood stasis, and dredge meridians to alleviate pain, which are core therapeutic principles in TCM for managing coronary heart disease. Pharmacologically, it acts by improving myocardial ischemia through the enhancement of coronary blood flow and the reduction of blood viscosity. Its primary herbal components, *Chuanxiong* (Rhizoma Chuanxiong) and *Honghua* (Flos Carthami), contain active compounds such as ligustrazine and hydroxysafflor yellow A, which exhibit vasodilatory and anti-platelet aggregation properties. It was approved by the China National Medical Products Administration (NMPA) as a modern TCM formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanhong Huoxue Capsule.